Microfluidic Devices for HIV Diagnosis and Monitoring at Point-of-Care (POC) Settings

Biosensors (Basel). 2022 Nov 1;12(11):949. doi: 10.3390/bios12110949.

Abstract

Human immunodeficiency virus (HIV) is a global epidemic; however, many individuals are able to obtain treatment and manage their condition. Progression to acquired immunodeficiency syndrome (AIDS) occurs during late-stage HIV infection, which compromises the immune system, making it susceptible to infections. While there is no cure, antiretroviral therapy can be used provided that detection occurs, preferably during the early phase. However, the detection of HIV is expensive and resource-intensive when tested with conventional methods, such as flow cytometry, polymerase chain reaction (PCR), or enzyme-linked immunosorbent assays (ELISA). Improving disease detection in resource-constrained areas requires equipment that is affordable, portable, and can deliver rapid results. Microfluidic devices have transformed many benchtop techniques to on-chip detection for portable and rapid point-of-care (POC) testing. These devices are cost-effective, sensitive, and rapid and can be used in areas lacking resources. Moreover, their functionality can rival their benchtop counterparts, making them efficient for disease detection. In this review, we discuss the limitations of currently used conventional HIV diagnostic assays and provide an overview of potential microfluidic technologies that can improve HIV testing in POC settings.

Keywords: CD4+ T cells; antibodies; detection assay; microfluidic; miniaturization.

Publication types

  • Review

MeSH terms

  • Flow Cytometry
  • HIV Infections* / diagnosis
  • Humans
  • Lab-On-A-Chip Devices*
  • Point-of-Care Systems
  • Point-of-Care Testing

Grants and funding

This research received no external funding.